A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Phase 1 Completed 210 enrolled Eli Lilly and Company

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

Timeline

Start: 2016-09-29
Primary completion: 2021-02-10
Completion: 2022-10-24

Publications

Bhagwat SV, McMillen WT, Cai S, Zhao B, Whitesell M, Shen W, Kindler L, Flack RS, Wu W, Anderson B, Zhai Y, Yuan XJ, Pogue M, Van Horn RD, Rao X, McCann D, Dropsey AJ, Manro J, Walgren J, Yuen E, Rodriguez MJ, Plowman GD, Tiu RV, Joseph S, Peng SB. ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine. Mol Cancer Ther. 2020 Feb;19(2):325-336. doi: 10.1158/1535-7163.MCT-19-0183. Epub 2019 Nov 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abemaciclib	Small molecule	—	Oral
Subject	Cetuximab	Monoclonal antibody	—	Intravenous
Subject	Encorafenib	Small molecule	—	Oral
Subject	Gemcitabine	Small molecule	—	Intravenous
Subject	Midazolam	Small molecule	—	Oral
Subject	Nab-paclitaxel	Small molecule	—	Intravenous
Subject	TEMUTERKIB	Small molecule	—	Oral

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Summary

Timeline

Publications

Drugs

Indications